Author

Nicolas Willand

InsermORCID 0000-0002-0784-0462Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Ainhoa LucíaiD· 1 shared Alain R. BaulardiD· 1 shared Albin A. M. LedingiD· 1 shared Alessia MichelottiiD· 1 shared Ana Picó· 1 shared Astrid Lenne· 1 shared Camille GrosseiD· 1 shared Christophe GuilhotiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Ainhoa LucíaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exploiting Vitamin B6 Dependency: BVL3572S Inhibits HisC and AlaA to Kill Mycobacterium tuberculosis

Zainab Edoo, Astrid Lenne, Camille Grosse, Marie Devaere, Marion Michel, Guillaume Caron, Ernesto Anoz‐Carbonell, Kamel Djaout, Rosangela Frita, Cyril Gaudin, Line Hofmann, Sophie Lecher, Véronique Mégalizzi, Alessia Michelotti, David Rengel, , Alain R. Baulard

This paper identifies BVL3572S as a compound that inhibits HisC and AlaA in Mtb, causing metabolic stress and showing synergy with existing drugs.

Cell chemical biology · Aug 1, 2026Peer-reviewedMicrobiology

In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis

Diana A. Aguilar-Ayala, Marie Sylvianne Rabodoarivelo, Maxime Eveque, Albin A. M. Leding, Lindsay Sonnenkalb, Ana Picó, Nicolas Willand, Natalya V. Serbina, Ulrika S. H. Simonsson, Ainhoa Lucía, Santiago Ramón‐García

This study evaluates the in vitro pharmacokinetics and pharmacodynamics of TBAJ-587 and its metabolites against M. tuberculosis, showing their efficacy and binding behavior in different media.

Frontiers in Microbiology · Jun 29, 2026Peer-reviewedPharmacology & Toxicology